Decreasing mortality with drotrecogin alfa in high risk septic patients A meta-analysis of randomized trials in adult patients with multiple organ failure and mortality >40% by GIOVANNI LANDONI et al.
 1www.signavitae.com
Decreasing mortality with 
drotrecogin alfa in high risk 
septic patients 
A meta-analysis of 
randomized trials in adult 
patients with multiple organ 
failure and mortality >40%
ABSTRACT
Objective. Sepsis is a complex inflammatory disease, rising in response to infection. Drotrecogin alfa, approved in 2001 for 
severe sepsis, has been withdrawn from the market. The aim of this study was to assess if drotrecogin alfa-activated can 
reduce mortality in the more severe septic patients.
Methods. We searched PubMed, Embase, Scopus, BioMedCentral, and in Clinicaltrials. gov databases to identify every 
randomized study performed on drotrecogin alfa-activated in any clinical setting in humans, without restrictions on dose or 
time of administration. Our primary end-point was mortality rate in high risk patients. Secondary endpoints were mortality in 
all patients, in patients with an Acute Physiology and Chronic Health Evaluation (APACHE) 2 score ≥ 25 and in those with 
an APACHE 2 score ≤25.
Results. Five trials were identified and included in the analysis. They randomized 3196 patients to drotrecogin alfa and 3111 
to the control group. Drotrecogin alfa was associated with a reduction in mortality (99/263 [37.6%] vs 115/244 [47.1%], risk 
ratios (RR) = 0.80[0.65; 0.98], p = 0.03) in patients with multiple organ failure and a mortality risk in the control group of 
>40%, but not in the overall population or in lower risk populations.
Conclusions. In high risk populations of patients with multiple organ failure and a mortality of >40% in the control group, 
Drotrecogin alfa may still have a role as a lifesaving treatment. No beneficial effect in low risk patients was found. An indivi-
dual patient meta-analysis including all randomized controlled trial on sepsis is warranted, along with new studies on similar 
drugs such as protein C zymogen.
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Introduction
Sepsis is a complex systemic inflam-
matory syndrome rising in response 
to severe infection, and is a leading 
cause of mortality and morbidity world-
wide. Eighteen million sepsis cases 
have been estimated to occur each 
year, with a mortality rate of nearly 
30%. (1) Sepsis is a multifaceted syn-
drome involving endothelial dysfunc-
tion, inflammatory response, immunity, 
deregulation of intercellular signaling, 
and cytokine storms. (2,3) Sepsis is 
classified as severe when organ dys-
function ensues.
Recombinant human activated pro-
tein C (drotrecogin alfa-activated) was 
approved in 2001 by FDA for severe 
septic patients at high risk of death, 
with an Acute Physiology and Chronic 
Health Evaluation (APACHE) II score 
higher than 25, while the European mar-
keting authorization was guaranteed for 
patients with severe sepsis and two or 
more organ failures. Recently, the drug 
was voluntarily withdrawn from the mar-
ket by the pharmaceutical company, 
in response to the findings of a large 
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randomized trial that questioned its 
risk/benefit ratio in patients with septic 
shock. (4)
Protein C is the plasmatic zymogen, 
and it is activated in the presence 
of thrombin - thrombomodulin com-
plex, thus limiting thrombin produc-
tion (through inactivation of factors Va 
and VIIIa) while also promoting fibrin-
olysis. Moreover, it may inhibit cytokine 
production, neutrophil activation and 
leukocyte adhesion. (5–8) Protein C 
shares the same benefits of its acti-
vated form (drotrecogin alfa) in septic 
shock, where it exerts a complex role 
between immunity, coagulation and 
inflammation.
Protein C seems safer than drotrecogin 
alfa, with no reported increase in bleed-
ing episodes. However high quality ran-
domized evidence on Protein C is lack-
ing. The finding of a significant positive 
effect of drotrecogin alfa on patients’ 
mortality could be relevant even if the 
drug is not commercialized anymore, 
as a similar but safer and much less 
studied drug exists: Protein C.
We therefore performed a meta-analy-
sis of randomized control trials (RCTs) 
to assess if drotrecogin alfa-activated 
can reduce mortality in the more severe 
septic patients, defined as those with 
multiple organ failure and a high mortal-
ity rate (> 40%).
Materials and methods 
Search Strategy
We searched PubMed, Embase, Sco-
pus, BioMedCentral, and the Clinicaltri-
als.gov database (updated September 
1st 2012) for relevant studies. Search 
was independently conducted by four 
trained investigators. The search stra-
tegy (9) included any randomized study 
ever performed on drotrecogin alfa-
activated (Xigris®; Eli Lilly and Compa-
ny, Indianapolis, IN, USA) in any clinical 
setting in humans, and is available in 
the Appendix. Moreover, pertinent refe-
rences of retrieved articles and reviews 
were retrieved to identify more articles. 
No language restriction was enforced. 
Study Selection
Results from database and literature 
queries were first independently exami-
ned at a title/abstract level by the four 
investigators, with divergences resol-
ved by consensus. Pertinent articles 
were retrieved as full text and analyzed 
adopting the following inclusion criteria: 
random allocation to treatment and 
comparison of drotrecogin alfa-acti-
vated versus control. There were no 
restrictions on dose or time of admini-
stration.
The exclusion criteria were: duplica-
te data, and non-adult studies. Two 
investigators independently assessed 
compliance with selection criteria and 
selected studies for the final analysis, 
with divergences finally resolved by 
consensus.
Data Abstraction and Study Charac-
teristics
Two authors extracted study end-points 
and main outcomes, study design, 
population, clinical setting, and trea-
tment duration. 
The primary end-point of the present 
investigation was the mortality rate in 
high risk patients, identified as having 
multiple organ dysfunction, and a high 
mortality rate in controls. A 40% mor-
tality rate was arbitrarily chosen as the 
cut-off to define high mortality rate. 
Secondary endpoints were mortality in 
all patients, mortality in patients with an 
APACHE 2 score ≥ 25 and in those with 
an APACHE 2 score ≤25.
Internal Validity and Risk of Bias Asse-
ssment
The internal validity and risk of bias of 
included trials was appraised by two 
independent reviewers according to 
Cochrane Collaboration methods, (10) 
with divergences resolved by consen-
sus. Publication bias was assessed by 
visual inspection of funnel plots.
Data Analysis and Synthesis
Computations were performed with 
RevMan 5. (11) Statistical heterogenei-
ty and inconsistency were measured 
using I2. Binary outcomes from indi-
vidual studies were analyzed in order 
to compute individual and pooled risk 
ratios (RR) with pertinent 95% confi-
dence intervals (CI, with equivalence 
set at 1, odds ratio (OR) <1 favoring 
the first treatment, and OR>1 favoring 
the second treatment), by means of 
Mantel-Haenszel method and with ran-
dom effect model (to better account for 
clinical and statistical variations). No 
continuous variables were included in 
analyses.
Statistical significance was set at the 
two-tailed 0.05 level for hypothesis 
testing and at 0.10 for heterogeneity 
testing. Unadjusted P values are repor-
ted throughout. This study was perfor-
med in compliance with The Cochrane 
Collaboration and PRISMA (Preferred 
Reporting Items for Systematic Reviews 
and Meta-Analyses) guidelines. (12)
Results 
Database searches and scanning of 
article bibliographies yielded a total of 
214 results. Excluding 188 non-perti-
nent titles or abstracts, we retrieved in 
complete form, and assessed accor-
ding to the selection criteria, 16 studies 
(figure 1). Six studies were further exc-
luded because they were not randomi-
zed. (1,13–17) Two studies were exclu-
ded because they involved a pediatric 
setting. (18,19) Two were further exc-
luded because they were conducted 
in other settings, like pancreatitis and 
pulmonary embolism. (20,21) One was 
excluded due to the administration of a 
study drug in controls. (22) Ultimately, 
therefore, we identified 5 eligible rando-
mized clinical trials for inclusion in the 
analysis. (4,8,23–25) 
Study Characteristics
The 5 included trials randomized 6307 
patients (3196 to drotrecogin alfa and 
3111 to the control group) (table 1). All 
these studies reported data on morta-
lity and were multicentre. Study quality 
appraisal indicated that studies were of 
variable quality (table 2) and that 3 of 
them had low risk of bias.
Quantitative Data Synthesis
Drotrecogin alfa was associated with a 
reduction in mortality (99/263 [37.6%] 
vs 115/244 [47.1%], RR=0.80[0.65; 
0.98], p for effect=0.03, p for hetero-
geneity=0.77, I2=0% with 507 patients 
and two studies included) (4,23) (figure 
2) in high risk patients, but not in the 
overall population or in other populati-
ons at lower risk (table 3). A trend was 
noted towards an excess in mortality in 
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the treatment group when low risk pati-
ents were considered (table 3).
Visual inspection of funnel plots did 
not identify a skewed or asymmetrical 
shape for mortality.
Discussion
The most important result of this study 
is that drotrecogin alfa reduces morta-
lity in high risk septic patients (identifi-
ed in this study as those with multiple 
organ failure and mortality in the control 
group higher than 40%). While another 
systematic review (26) on the effects 
of drotrecogin alfa included randomi-
zed and non randomized studies, this 
meta-analysis was based solely on high 
quality randomized controlled trials. 
The preset study also confirms that dro-
trecogin alfa does not reduce mortality 
in the overall population of septic pati-
ents, as previously described. (23,27) 
Moreover, in low risk patients with an 
APACHE II score≤25, no significantly 
higher risk of death was found. This 
finding is reassuring when confronted 
with the increased risk for severe com-
plications (bleeding) described in the 
ADDRESS study.
The Prospective Recombinant Human 
Activated Protein C Worldwide Evalua-
tion in Severe Sepsis (PROWESS) trial 
(23) and its following subgroup anal-
yses (28,29) found a consistent reducti-
on in mortality in patients at higher risk of 
death, as defined by multi-organ failure 
or APACHE II scores higher than 25. 
Early enthusiasm left room for a more 
cautious interpretation after publication 
of the Administration of drotrecogin Alfa 
(Activated) in Early Stage Severe Sep-
sis (ADDRESS) trial, (24,30) conducted 
on patients with severe sepsis and low 
risk of death. This trial was termina-
ted earlier for safety concerns by the 
monitoring committee. No difference 
was shown on 28thday or in-hospital 
mortality between drotrecogin alfa and 
placebo, while an increase in serious 
bleeding in the drotrecogin alfa group 
was detected.
The subsequent PROWESS-SHOCK 
trial was recently published by Ranieri 
et al. (4) This multicenter randomized 
controlled trial was conducted to test 
the hypothesis that drotrecogin alfa 
could reduce mortality in patients with 
septic shock. This population of pati-
ents was identified from the previous 
published trials as potentially benefi-
tting from protein C activated. However, 
no significant reduction in mortality was 
found at 28 days (26.4% in drotreco-
Table 1. Description of included studies.
First author Journal Year Multicentric Follow up Case Controls Dose Comparator
Bernard (8) Crit Care Med 2001 yes 28 days 90 41
From 1 to 30 
ug/kg/min
Placebo
Bernard (23) New Engl J Med 2001 yes 28 days 850 840 24 ug/kg/min Placebo
Abraham (24) New Engl J Med 2005 yes 1 year 1316 1297 24 ug/kg/min Placebo
Dhainaut (25) Intensive Care Med 2009 yes 90 days 94 99 24 ug/kg/min Placebo
Ranieri (4) New Engl J Med 2012 yes 90 days 846 834 24 ug/kg/min Placebo





























Bernard (8) Unclear Unclear Yes Yes Unclear Yes Yes Unclear Intermediate
Bernard (23) Yes Yes Yes Yes Yes Yes Yes Yes Low
Abraham (24) Yes yes Yes Yes Yes Yes Yes Yes Low
Dhainaut (25) Unclear Unclear Yes Yes Yes Yes Yes Yes Intermediate
Ranieri (4) Yes Yes Yes Yes Yes Yes Yes Yes Low
Table 3. Results of pooled estimates in different population of patients.
Populations Mortality Cases Mortality controls RR 95% CI
p for 
effect
p for heterogeneity I2
High risk 354/995 (35.6%) 390/975 (40%) 0.93 0.69-1.24 0.6 0.004 82%
Low risk 472/2010 (23.5%) 358/1980 (18%) 1.29 0.82-2.04 0.28 0.001 92%
Overall 739/3196 (23.1%) 726/3111 (23.4%) 1.00 0.84-1.19 1 0.02 65%
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gin alfa group vs 24.2% in controls, 
p=0.31) or 90 days (34.1% in drotre-
cogin alfa group vs 32.7% in controls), 
nor in subgroups of patients defined by 
organ failure or APACHE II scores.
Drotrecogin alfa was on the market 
for ten years before being withdrawn. 
In this decade sepsis treatment has 
dramatically improved, with the deve-
lopment of new therapeutic strategies: 
the introduction of sepsis bundles, (31) 
including early goal directed therapy, 
(32) the use of protective lung ventila-
tion, (33) and other interventions which 
have been more recently questioned, 
like glycemic control (34) and cortico-
steroid therapy. (35)
These new strategies have reduced 
mortality up to 50% (36,37) in septic 
patients, a finding confirmed in recent 
trials. (38–40) For this reason the com-
parison of earlier studies on drotrecogin 
alfa with more recent studies may be 
misleading, due to the differences in 
treatment. The consistent beneficial 
effect of drotrecogin alfa on mortality 
was indeed clearly demonstrated only 
in the first studies (PROWESS), when 
mortality in the standard treatment 
group was around 40%.
The APACHE II score was developed 
by Knaus et al. (41) to graduate criti-
cally ill patients’ prognosis. However, 
with improvement in sepsis treatment, 
the reliability of APACHE II scores in 
predicting mortality is reduced or at 
least modified compared with studies 
published several years ago. Consequ-
ently, to reduce confounding due to 
higher survival rate in more recent studi-
es, in this study we defined a subgroup 
of very high risk patients. We consi-
dered not only the APACHE 2 score 
or the number of organs involved, but 
we adopted the control group mortality 
rate as a stable index of poor prognosis 
among decades. Despite the secular 
trend of improved survival, in this popu-
lation of high risk patients drotrecogin 
alfa treatment was associated with a 
significant reduction in mortality. 
The new therapeutic strategies for 
sepsis focus on timely interventions in 
order to limit decline of organ function. 
Early intervention limits the subsequ-
ent cascade of endothelial and cellular 
dysfunction that leads to an ominous 
prognosis. Drotrecogin alfa (activated) 
may still be beneficial, thanks to its pro-
fibrinolytic anti-inflammatory action, in 
patients with very poor prognosis where 
both full blown endothelial dysfunction 
and compromise of inflammatory and 
coagulation cascade are present. 
The PROWESS-SHOCK (4) showed the 
same trend in mortality in this high risk 
subpopulation of patients (RR 0.83 [95% 
CI 0.6-1.14]), but was underpowered to 
reach statistical significance. Moreover, 
no increase in serious bleeding was 
detected (p=0.81), a reassuring finding 
that counterbalance the results of Abra-
ham et al. (24)
Our results are consistent with those 
from Kalil et al. that found a benefici-
al effect of drotrecogin alfa in septic 
patients through a meta-analysis that 
included high and low quality studies, 
like case series and non-randomized 
controlled trial and reporting drotreco-
gin effect on the overall population of 
septic patients. (42)
Given these results, even if drotreco-
gin alfa has been withdrawn from the 
market, the commercial availability of 
its twin molecule Protein C zymogen is 
an exciting alternative. (43-45) High risk 
septic patients may still benefit from 
protein C action, and while further anal-
ysis should be conducted on drotre-
cogin alfa, at least with an individual 
patient meta-analysis, the effect of Pro-
tein C zymogen should be evaluated in 
further trials. 
Limitations
The limitations of this study are those 
specifically related to meta-analysis, 
including suboptimal quality of the 
included studies. Moreover, in this 
Figure 1.  Flow diagram for selection of articles.
CI, confidence interval; RR, risk ratio.
Figure 2.  Forest plot for the risk of mortality in very high risk patients. 
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study we identified high risk patients 
through an ex-post analysis that iden-
tified the highest risk patient despite 
improved patient prognosis. A cut-off 
of 40% mortality was arbitrarily chosen 
to identify this high risk population of 
patients despite the secular trend of 
improved survival. As this population 
of patients was identified by an ex-post 
analysis, it cannot be translated as is in 
the clinical setting without the develo-
pment of new predictive scores. 
Conclusion
In high risk patients with multiple organ 
failure and high mortality rate in the 
control group, drotrecogin alfa may still 
have a role as a life saving treatment. 
No beneficial effect in lower risk pati-
ents was found. Since no new large 
RCT will probably be conducted on 
this drug, now withdrawn from the mar-
ket, an individual patient meta-analysis 
including all randomized controlled tri-
als on sepsis is warranted, along with 
new studies on similar drugs such as 
protein C zymogen.
APPENDIX 1
(“Drotrecogin alfa” “protein C activated” OR “xigris”) AND (sepsis OR “septic shock”) AND (randomised controlled trial[pt] OR controlled 
clinical trial[pt] OR randomised controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR single-blind method[mh] 
OR clinical trial[pt] OR clinical trials[mh] OR (clinical trial[tw] OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] 
OR blind[tw])) OR (latin square[tw]) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative 
study[tw] OR follow-up studies[mh] OR prospective studies[mh] OR cross-over studies[mh] OR control[tw] OR controls[tw] OR controlled[tw] 
OR prospectiv*[tw] OR volunteer*[tw]) NOT (animal[mh] NOT human[mh]) NOT (comment[pt] OR editorial[pt] OR meta-analysis[pt] OR 
practice-guideline[pt] OR review[pt])).
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